Observe Medical ASA: Disclosure of major shareholdings following completion of the Private Placement and Subsequent Offering

13 Oct 2025 21:00 CEST

Reference is made to the stock exchange announcements published by Observe
Medical ASA (the "Company") regarding (i) the issuance of 20,000,000 new shares
to complete the private placement at the extraordinary general meeting held on
10 October 2025 (the "Private Placement"), and (ii) the final result of the
subsequent offering announced on 13 October 2025 (the "Subsequent Offering").

Following completion of the Private Placement, the total number of shares in the
Company will be 112,148,412. Following completion and registration of both the
Private Placement and the Subsequent Offering, the total number of shares in the
Company will be 136,148,412, each with a nominal value of NOK 0.42.

Subject to the completion of the Private Placement and the Subsequent Offering,
the following shareholders have crossed disclosure thresholds pursuant to
section 4-2 of the Norwegian Securities Trading Act:

· Songa Capital AS will hold 10,000,000 shares in the Company and Songa X AS
will hold 2,500,000 shares in the Company, jointly representing 11.15% of the
share capital and votes in the Company following the Private Placement and
before the Subsequent Offering, and 9.18% of the share capital and votes in the
Company after the final allocation of the Subsequent Offering, consequently
crossing the disclosure threshold of 5% of the votes in the Company.

· Navamedic ASA held 12,564,279 shares, representing 13.63% of the share
capital and votes prior to the Private Placement and the Subsequent Offering.
Following completion of the Private Placement, Navamedic ASA will hold 11.20%,
and after the Subsequent Offering 9.23%, and has therefore fallen below the 10%
disclosure threshold.

· R Investment Company AS held 10,103,571 shares, representing 10.96% of the
share capital and votes prior to the Private Placement and the Subsequent
Offering. Following completion of the Private Placement, R Investment Company AS
will hold 9.01% of the share capital and votes, and after the Subsequent
Offering R Investment Company AS will hold 10,703,684 shares, representing 7.86%
of the share capital and votes, and has therefore fallen below the 10%
disclosure threshold.

· Seed Capital AS held 5,016,155 shares, representing 5.44% of the share
capital and votes prior to the Private Placement and the Subsequent Offering.
Following completion of the Private Placement, Seed Capital AS will hold 4.47%
of the share capital and votes, and after the Subsequent Offering Seed Capital
AS will hold 5,236,268 shares, representing 3.85% of the share capital and
votes, and has therefore fallen below the 5% disclosure threshold.

· Jiangsu Hongxin Medical Technology Co., Ltd. held 6,000,000 shares,
representing 6.51% of the share capital and votes prior to the Private Placement
and the Subsequent Offering. Following completion of the Private Placement,
Jiangsu Hongxin Medical Technology Co., Ltd. will hold 5.35% of the share
capital and votes, and after the Subsequent Offering Jiangsu Hongxin Medical
Technology Co., Ltd  will hold 6,000,000 shares, representing 4.41% of the share
capital and votes, and has therefore fallen below the 5% disclosure threshold.

The changes in shareholdings are due solely to dilution and/or the allocation of
new shares in connection with the Private Placement and the Subsequent Offering,
and not to any other direct acquisition or disposal of shares.

This disclosure is made pursuant to section 4-2 of the Norwegian Securities
Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site